Phase I Study of Aurora A Kinase Inhibitor MLN8237 in Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics, and Bioavailability of Two Oral Formulations
Clinical Cancer Research, 08/09/2012
Dees EC et al. – This first–in–human trial of MLN8237 showed tolerability and favorable pharmacokinetics in this patient population. The recommended phase II dose of MLN8237 is 50mg twice daily orally for 7 days in 21–day cycles, which is being evaluated further in the treatment of various solid tumors and hematologic malignancies.